<sup>90</sup>Y/<sup>177</sup>Lu-DOTATOC: From Preclinical Studies to Application in Humans

<sup>90</sup>Y/<sup>177</sup>Lu-DOTATOC: From Preclinical Studies to Application in Humans

The PRRT (Peptide Receptor Radionuclide Therapy) is a promising modality treatment for patients with inoperable or metastatic neuroendocrine tumors (NETs). Progression-free survival (PFS) and overall survival (OS) of these patients are favorably comparable with standard therapies. The protagonist in...

Full description

Bibliographic Details
Main Authors: Licia Uccelli, Alessandra Boschi, Corrado Cittanti, Petra Martini, Stefano Panareo, Eugenia Tonini, Alberto Nieri, Luca Urso, Matteo Caracciolo, Luca Lodi, Aldo Carnevale, Melchiore Giganti, Mirco Bartolomei
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Pharmaceutics
Subjects:
[<sup>177</sup>Lu]Lu-DOTATOC
[<sup>90</sup>Y]Y-DOTATOC
PRRT
neuroendocrine tumors
Online Access:https://www.mdpi.com/1999-4923/13/9/1463

Similar Items

Similar Items